目的 探討喹硫平、奧氮平聯(lián)合丙戊酸鈉緩釋片對(duì)維族雙相障礙精神病臨床療效的影響。方法 選擇2015年6月—2016年6月在烏魯木齊市第四人民醫(yī)院治療雙相障礙精神病的患者100例，隨機(jī)分為2組，每組50例，對(duì)照組患者服用奧氮平聯(lián)合丙戊酸鈉緩釋片，觀察組患者服用喹硫平聯(lián)合丙戊酸鈉緩釋片，服藥1、4、8周時(shí)患者于醫(yī)院進(jìn)行復(fù)查，填寫(xiě)17項(xiàng)HMDM評(píng)分表、BRMD評(píng)分表以及GSI-IS評(píng)分表評(píng)估兩組患者在不同時(shí)間的抑郁、躁狂情況和臨床療效。結(jié)果 兩組患者在治療期間，臨床癥狀減輕，治療1、4、8周時(shí)HMDM評(píng)分、BRMD評(píng)分以及GSI-IS評(píng)分均顯著低于治療前（P＜0.05），且隨療程的延長(zhǎng)，癥狀趨于減輕甚至消失；觀察組各量表評(píng)分比對(duì)照組低，但是統(tǒng)計(jì)學(xué)分析無(wú)顯著差異。記錄兩組患者治療過(guò)程中發(fā)生不良反應(yīng)的情況，結(jié)果顯示觀察組患者不良反應(yīng)的總發(fā)生率和頭暈嗜睡的發(fā)生率較對(duì)照組明顯降低（P＜0.05）。結(jié)論 奧氮平或喹硫平聯(lián)合丙戊酸鈉緩釋片可以有效控制維族雙相障礙患者抑郁、躁狂癥狀，且?jiàn)W氮平聯(lián)合丙戊酸鈉緩釋片可以顯著降低不良反應(yīng)發(fā)生率，值得臨床推廣應(yīng)用。

Objective To explore the effect of quetiapine or olanzapine combined with sodium valproate on curative for Uighur patients with bipolar disorder. Methods Totally 100 Uighur patients with bipolar disorder were enrolled in The Fourth People's Hospital of Urumqi from June 2015 to June 2016, of which patients divided into two groups randomly, the patients of control group (n = 50) accepted sodium valproate combined with olanzapine, and patients in observation group (n = 50) were administered with sodium valproate combined with quetiapine. The patients taking medicine were reviewed at the hospital after 1, 4, and 8 weeks, and the depression and manic state and severity of clinical efficacy with 17 HMDM score, BRMD score and GSI-IS score questionnaire were evaluated. Results Each score of questionnaire was significantly lower than that before treatment (P< 0.05), all patients' clinical symptoms were relieved obviously, and symptoms tended to reduce or even disappeared with the extension of the course of treatment. Each score of questionnaire in observation group was lower than that in control group, bur difference has no statistical significance; Comparing the incidence of adverse reaction of two groups, the patients with dizziness and sleepiness in observation group were significantly decreased compared with observation group (P< 0.05). Conclusions Quetiapine or olanzapine combined with sodium valproate for Uighur patients with bipolar disorder deserved popularization in clinic as the efficacious remission of depression and manic state.